Cellular senescence in liver diseases: From mechanisms to therapies.

Alcoholic liver disease Cellular senescence Hepatocellular carcinoma Liver fibrosis Nonalcoholic fatty liver disease

Journal

International immunopharmacology
ISSN: 1878-1705
Titre abrégé: Int Immunopharmacol
Pays: Netherlands
ID NLM: 100965259

Informations de publication

Date de publication:
Aug 2023
Historique:
received: 27 10 2022
revised: 05 06 2023
accepted: 14 06 2023
medline: 26 7 2023
pubmed: 30 6 2023
entrez: 29 6 2023
Statut: ppublish

Résumé

Cellular senescence is an irreversible state of cell cycle arrest, characterized by a gradual decline in cell proliferation, differentiation, and biological functions. Cellular senescence is double-edged for that it can provoke organ repair and regeneration in physiological conditions but contribute to organ and tissue dysfunction and prime multiple chronic diseases in pathological conditions. The liver has a strong regenerative capacity, where cellular senescence and regeneration are closely involved. Herein, this review firstly introduces the morphological manifestations of senescent cells, the major regulators (p53, p21, and p16), and the core pathophysiologic mechanisms underlying senescence process, and then specifically generalizes the role and interventions of cellular senescence in multiple liver diseases, including alcoholic liver disease, nonalcoholic fatty liver disease, liver fibrosis, and hepatocellular carcinoma. In conclusion, this review focuses on interpreting the importance of cellular senescence in liver diseases and summarizes potential senescence-related regulatory targets, aiming to provide new insights for further researches on cellular senescence regulation and therapeutic developments for liver diseases.

Identifiants

pubmed: 37385123
pii: S1567-5769(23)00845-7
doi: 10.1016/j.intimp.2023.110522
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

110522

Informations de copyright

Copyright © 2023 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Ting Ge (T)

School of Pharmacy, Nantong University, Nantong, Jiangsu, China.

Yunyun Shao (Y)

School of Pharmacy, Nantong University, Nantong, Jiangsu, China.

Xiaofeng Bao (X)

School of Pharmacy, Nantong University, Nantong, Jiangsu, China.

Wenxuan Xu (W)

School of Life Science and Technology, China Pharmaceutical University, Nanjing, Jiangsu, China. Electronic address: xwx8991@163.com.

Chunfeng Lu (C)

School of Pharmacy, Nantong University, Nantong, Jiangsu, China. Electronic address: ntdxlcf@ntu.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH